Detection of Myocardial Dysfunction in Non-severe Subarachnoid Hemorrhage (WFNS 1-2) Using Speckle-tracking Echocardiography (STRAIN)

Left Ventricular Dysfunction Clinical Trial

— SAH-STRAIN  

Official title:

Detection of Myocardial Dysfunction in Non-severe Subarachnoid Hemorrhage (WFNS 1-2) Using Speckle-tracking Echocardiography (STRAIN)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03761654
• Other study ID #: CHUBX 2018/51
• Status: Completed
• Start date: January 2, 2019
• Est. completion date: January 1, 2021

Study information

• Verified date: January 2021
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Subarachnoid hemorrhage (SAH) can cause transient myocardial dysfunction. Recently, it have been reported that myocardial dysfunctions that occur in SAH are associated with poor outcomes. It therefore appears essential to detect theses dysfunctions with the higher sensitivity as possible. Strain measurement using speckle-tracking echocardiography may detect myocardial dysfunction with great sensitivity. The main objective of this study is to assess the prevalence of myocardial dysfunction in "non-severe" SAH (defined by a WFNS grade 1 or 2), using speckle-tracking echocardiography. This study also aims to analyse Strain measurement with classical echocardiography and serum markers (troponin, BNP) of cardiac dysfunction.

Description:

Cardiac complication, occurring in the early phase of SAH has been well described. It seems that the pathophysiological mechanism involves vegetative hyperactivity due to the acute cerebral injury. It has been shown that stress cardiomyopathy is associated with delayed cerebral ischemia (DCI) and poor outcomes. Manifestations of stress cardiomyopathy are changes in electrocardiogram, release of cardiac biomarkers such as troponin and BNP, and echography evidence of impaired left ventricle ejection fraction with the use of Simpson technique and regional wall motion abnormalities. These two techniques bear intra-observer variability. A new method is available to assess left ventricular contractility at the bedside. Two-dimensional speckle-tracking images with echocardiography allows one to track a natural myocardial marker within the myocardium by standard transthoracic echocardiography. It provides unique insights into myocardial function such as tissue deformations and strain rate, which is the rate of deformation. This method is more sensitive than classical echographic left ventricular ejection fraction evaluation and bears very low interobserver variability. The Global Longitudinal Strain (GLS) is the most studied parameter.

Early detection of cardiac dysfunction in SAH followed by appropriate monitoring and management may improve outcome in SAH. This is a prospective, observational and mono-center study.

Patients with "non-severe" SAH will benefit from an echocardiography where Left Ventricular Ejection Fraction (LVEF) and GLS will be assessed on day 1, 3 and 7 following the acute injury.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 117
• Est. completion date: January 1, 2021
• Est. primary completion date: December 25, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patient older than 18 years

• hospitalized in neuro-intensive care unit with a "non-severe" subarachnoid hemorrhage (WFNS 1 or 2)

Exclusion Criteria:

• low echogenicity

• history of cardiac malformation or cardiac surgery

• severe valvular heart disease

• dilated cardiomyopathy

• acute coronary syndrome

• permanent arrythmia

• patient refusal

Related Conditions & MeSH terms

• Cardiomyopathies
• Hemorrhage
• Left Ventricular Dysfunction
• Stress Cardiomyopathy
• Subarachnoid Hemorrhage
• Subarachnoid Hemorrhage (SAH)
• Takotsubo Cardiomyopathy
• Ventricular Dysfunction
• Ventricular Dysfunction, Left

Intervention

Diagnostic Test:
• Global Longitudinal Strain measure
Global Longitudinal Strain measure on day 1 of hospitalization

Locations

Country	Name	City	State
France	CHU de Bordeaux	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global Longitudinal Strain	It is calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.	Day 1 of hospitalization
Secondary	Global Longitudinal Strain	is calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.	Day 3 of hospitalization
Secondary	Global Longitudinal Strain	is calculated using values of longitudinal strain measured in the three-,four-, and two-chamber of the left ventricle of the heart. GLS is expressed as percentage. Strain is a measure of myocardial muscle fiber shortening during contraction and is calculated as the systolic segment shortening between end-systolic (ES) segment length (L) and end-diastolic (ED) length: strain = (-LES - LED)/LED x 100 %.	Day 7 of hospitalization
Secondary	Change of Left Ventricular Ejection Fraction using Simpson technique		Days 1, 3 and 7 of hospitalization
Secondary	Change in serum troponin level		Days 1, 3 and 7 of hospitalization
Secondary	Change in brain natriuretic peptide (BNP) level		Days 1, 3 and 7 of hospitalization
Secondary	Electrocardiogram abnormalities	Abnormalities expected: abnormal Q or QS wave (=30 ms or a pathological R wave in V1 to V2); ST de- pression (ST depression = 0.1 mV, 80 ms post-J point); ST elevation (ST elevation = .1 mV); peaked upright T wave (prominent peaked T wave); T-wave inver- sion (pathologic T-wave inversion); nonspecific ST- or T-wave changes	Up to day 7 of hospitalization